Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Feb 15, 2017 1:10pm
193 Views
Post# 25849907

Zenith BIO CEO & Investor Conference 2017

Zenith BIO CEO & Investor Conference 2017Some great pick up and comments by fouremm, Bear, and nextblockbuster on Agora's Zenith discussion.

Fouremm noted that on page 3 of the Zenith presentation that the enterprise value of Zenith is now put at $500 million. Bear pointed out that it was $160 million in Dec 2016.

Poosible speculation from me is might this be related to the (Pfizer acquisition of one half enzalutimide - for $14 billion) and the zen3694 combined with enzalutimde trial that started dosing on mCRPC patients and might it suggest would could hear some positive results on the non enzalutimide phase which is now past 6 months for the longest dosed patient?

GLTA
Toinv
Bullboard Posts